Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TransThera to Start US Trials of Novel BTK Inhibitor

publication date: Feb 18, 2022

Nanjing TransThera Sciences was granted permission to start US trials of its non-covalent reversible Bruton's Tyrosine Kinase (BTK) inhibitor in patients with B-cell lymphomas. The company said its non-covalent BTK candidate, TT-01488, is differentiated from the five already-approved BTK drugs because each of the five form covalent bonds with the C481 site of BTK. When the C481S mutation occurs, patients become resistant to these drugs. The global market for BTK drugs is over $7 billion and growing, especially in China. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital